Multidrug resistance: molecular and clinical aspects

Area of Science:

• Molecular Biology
• Genetics
• Oncology

Background:

• Multidrug resistance (MDR) is a significant challenge in cancer chemotherapy, characterized by acquired cellular resistance to multiple cytotoxic drugs.
• The multidrug resistance gene (mdr) family, particularly the human mdr1 gene, is a key area of study for understanding MDR mechanisms.
• The mdr1 gene encodes the P-170 glycoprotein, a membrane protein hypothesized to function as a drug-efflux pump, expelling various chemotherapeutic agents from cells.

Purpose of the Study:

• To investigate the role of the human mdr1 gene in the molecular mechanisms of multidrug resistance.
• To explore the evolutionary basis of the mdr1 gene's bipartite structure, suggesting a gene fusion event.
• To re-evaluate the clinical significance of the mdr1 gene in cancer treatment.

Main Methods:

• Analysis of the human mdr1 gene structure and function.
• Review of existing literature on multidrug resistance and the mdr1 gene.
• Comparative evolutionary analysis of the mdr1 gene family.

Main Results:

• The human mdr1 gene encodes the P-170 glycoprotein, implicated in drug efflux and cellular resistance.
• The mdr1 gene exhibits a bipartite structure, indicative of an evolutionary gene fusion event.
• Current research suggests the mdr1 gene may serve as a marker of tumor aggressiveness rather than the direct cause of clinical chemoresistance.

Conclusions:

• The mdr1 gene plays a crucial role in the molecular mechanisms underlying multidrug resistance.
• The evolutionary history of the mdr1 gene provides insights into its structural organization.
• The clinical interpretation of the mdr1 gene's significance is evolving, shifting focus from a direct cause of resistance to a potential indicator of tumor aggressiveness.